Anastrozole mediated modulation of mitochondrial activity by inhibition of mitochondrial permeability transition pore opening: An initial perspective

Authors:
  • SGSubhajit Ghosh
    Subhajit Ghosh
  • NCNeha Choudhary
    Neha Choudhary
  • MFMohammed Faruq
    Mohammed Faruq
  • PIPrem Kumar Inderganti
    Prem Kumar Inderganti
  • RSRavindra Kumar Saran
    Ravindra Kumar Saran
  • HSHaseena Sait
    Haseena Sait
  • SKSeema Kapoor
    Seema Kapoor

Abstract
Background: Mitochondrial permeability transmembrane pore [mPTP] plays a vital role in alteration of the structure and function of mitochondria. Cyclophillin D is a mitochondrial protein that regulates mPTP function and a known drug target for therapeutic studies involving mitochondria. While aromatase inhibitor’s role on mPTP has been previously studied, the role of anastrazole on mPTP is not completely elucidated. Methods: The role of anastrozole in modulating the mPTP was evaluated by docking and molecular dynamics using human cyclophillin D data. Peripheral blood mononuclear cells [PBMCs] of patients with mitochondrial disorders and healthy controls were treated with anastrazole and evaluated for mean fluorescence by flow cytometer. Spectrophotometry was employed for total ATP level estimation. Findings: Anastrozole – cyclophillin D complex is more stable when compared to cyclosporine A – cyclophillin D. Anastrozole performed better than cyclosporine in inhibiting mPTP pore. Additional effects included reduction in mitochondrial swelling and mitochondrial membrane depolarization, decreased super oxide generations, caspase 3 intrinsic activity and cellular apoptosis levels and increase in ATP levels. Interpretation: These results highlights the potency of anastrozole as a promising agent in ameliorating the phenotype by inhibiting the opening of mPTP pore. However, larger functional studies are required to validate the efficacy of this molecule as a therapeutic agent in mitochondrial disorders.

This publication has 46 references indexed in Scilit: